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impact of this on the treatment of asthma. METHODS: Our
submission to NICE reviewing the relative value of alternative
products, utilised a cost-minimisation approach, recognising that
there was little evidence of clinical differentiation between the
ICS. RESULTS: It was estimated that a total switch to QVAR
upon withdrawal of CFC based BDP, would result in only a
modest 6% increase in costs to the NHS, but could result in
overall cost savings if it were substituted for more costly ICS
alternatives, such as ﬂuticasone propionate or budesonide. CON-
CLUSION: There remain concerns that NICE may overlook the
current political and socioeconomic imperatives and provide
Guidance that does not consider appropriate BDP dosing or
recognise that the environment will change over its period of
jurisdiction.
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OBJECTIVES: Frequent use of short-acting beta agonists (SABA)
inhalers, along with insufﬁcient use of concurrent steroid inhal-
ers, is often the cause of suboptimal management of the disease.
The aim of the study is to identify the heavy purchasers of SABA
and improve the management of there disease. METHODS: All
Maccabi Healthcare Services (MHS) patients in two areas in the
Shfela district who consumed al least 4 SABA inhalers during
2005 were identiﬁed using MHS’s computerized database. The
patients’ primary care physicians (PCP) were briefed with the
ﬁndings and where presented the current evidence based medi-
cine (EBM) clinical guidelines for proper asthma treatment in a
group meetings with pulmonologist. Later the PCP attend to two
days workshop dealing with appropriate asthma treatment,
patient’s adherence and practicing clinical scenarios with profes-
sional actors. A 3rd meeting included case presentations and
further discussions with a pulomonologist. A control group con-
sisted of patients of PCPs in other areas in the Shfela district
which didn’t participate in the study. RESULTS: One hundred six
patients were in the intervention group. 85 required more then 2
SABA inhalers in the ﬁrst 6 month after intervention (decrease of
20%). In the control group there was a 4% increase in patients
using more than 2 SABA inhalers during the same period (185 to
193). CONCLUSION: We have observed a signiﬁcant improve-
ment in SABA consumption. This improvement applies that edu-
cational efforts on applying EBM clinical guidelines for proper
asthma treatment and providing simple tools for dealing with
patients’ adherence, can improve management and control of
asthma and can lower asthma’s treatment expenses. We suggest
similar interventions on other chronic diseases.
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OBJECTIVES: Clinical efﬁcacy and cost-effectiveness of immu-
notherapy in allergic disease caused by various allergens is dem-
onstrated by several published studies, but economic value is still
far from being appreciated by local decision makers. Scope of
this work was to provide the Regional decision makers with real
world information on the use and impact of immunotherapy in
terms of efﬁcacy on symptoms, use and cost of drugs in patients
affected by rhinoconjunctivitis (RC) with or without asthma (A),
caused by ragweed seasonal allergy. METHODS: Observational
study, of precoseasonal sublingual (SLIT) or preseasonal subcu-
taneous immunotherapy (SCIT) versus non-immunotherapy
(NSIT). Patients enrolled by a network of specialist centres from
Lombardia, were randomly assigned to one of the study groups
and were allowed to take any additional medication needed to
control RC and A symptoms; effectiveness was measured as
global symptom score rated by the patient on a VAS at last visit;
drug consumption was measured as days of medication recorded
by the patient on a weekly diary card during the peak season;
drug cost was calculated by applying Italian NHS prices.
RESULTS: For the ﬁrst year of immunotherapy, 163 adults were
analyzed (SLIT N = 67 M = 48%, age 39+/-9.1; SLIT N = 34
M = 62%, age 41+/-8.1; NSIT N = 62 M = 53%, age 36+/-9.2);
25% of SLIT patients were affected by A as compared to 47% of
SCIT and 37% of NSIT patients; 55% of SLIT patients were
treated with high dose SLIT. The mean number of drug treatment
days/patient was lower for SLIT patients 26.15+/-30.1 vs. NSIT
58.7+/-43.4 (p < 0.0001) and for SCIT patients 33.0+/-45.7 vs
NSIT 58.7+/-43.4 (p < 0.05); similarly the mean total cost/
patient of drug treatment was lower with SLIT €28.19 vs SCIT
€33.9 and NSIT €59.2. CONCLUSION: SLIT and SCIT can
effectively reduce use and cost of drug treatment in adults
affected by rhinoconjunctivitis with/without asthma caused by
ragweed in Lombardia.
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OBJECTIVES: Formoterol/budesonide (BUD/FORM) and sal-
meterol/ﬂuticasone propionate (SAL/FLU) have been shown to
be effective in the treatment of asthma. This retrospective, obser-
vational study compared characteristics of patients initiating
treatment with BUD/FORM or SAL/FLU in routine clinical prac-
tice, subsequent treatment outcomes and resource utilisation.
METHODS: A cohort of German patients diagnosed with
asthma, followed from 12 months before to 12 months after
treatment initiation with BUD/FORM or SAL/FLU, was ex-
tracted from a longitudinal, primary care database of records
collected from June 2000 to June 2006. The primary outcome
was the proportion of successfully treated patients deﬁned
according to utilisation of short-acting beta-agonists (SABA) and
switches or addition of controller medications during the post-
index year. Secondary outcomes included resource utilisation and
acute exacerbations, deﬁned as at least one oral corticosteroid
(OCS) prescription and/or hospitalisation related to asthma.
Regression models were used to adjust for patient characteristics,
including treatment history. RESULTS: The BUD/FORM and
SAL/FLU groups included 1,456 and 982 patients, respectively.
Prior to treatment initiation, patients in the BUD/FORM group
received less asthma-related OCS prescriptions (mean difference:
-0.049, p = 0.0328) but utilisation of SABA, ICS and LABA was
similar. In the year following treatment initiation, patients initi-
ating on BUD/FORM had a greater probability of treatment
success (OR = 1.54, p = 0.0001), fewer acute exacerbations
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